{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:09:53Z","timestamp":1791306593427,"version":"4.3.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008069","name":"University of California San Francisco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.bone.2021.116297","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T02:50:44Z","timestamp":1639450244000},"page":"116297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Bisphosphonates and the risk of atypical femur fractures"],"prefix":"10.1016","volume":"156","author":[{"given":"Dennis M.","family":"Black","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Condra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette L.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bone.2021.116297_bb0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1210\/er.2018-00001","article-title":"Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management","volume":"40","author":"Black","year":"2019","journal-title":"Endocr. Rev."},{"issue":"8","key":"10.1016\/j.bone.2021.116297_bb0010","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bone.2021.116297_bb0015","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological Management of Osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.bone.2021.116297_bb0020","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1210\/jc.2012-1027","article-title":"Benefits and risks of bisphosphonate therapy for osteoporosis","volume":"97","author":"Khosla","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"19","key":"10.1016\/j.bone.2021.116297_bb0025","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMc062268","article-title":"Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis","volume":"355","author":"Armamento-Villareal","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bone.2021.116297_bb0030","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1302\/0301-620X.89B3.18146","article-title":"Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution","volume":"89","author":"Goh","year":"2007","journal-title":"J. Bone Joint Surg."},{"issue":"11","key":"10.1016\/j.bone.2021.116297_bb0035","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2021.116297_bb0040","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/jbmr.1893","article-title":"Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis","volume":"28","author":"Gedmintas","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bone.2021.116297_bb0045","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","article-title":"The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension","volume":"98","author":"Bone","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bone.2021.116297_bb0050","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00198-015-3355-z","article-title":"Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review","volume":"27","author":"Selga","year":"2016","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.bone.2021.116297_bb0055","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/17453674.2016.1277412","article-title":"Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab","volume":"88","author":"Austin","year":"2017","journal-title":"Acta Orthop."},{"issue":"12","key":"10.1016\/j.bone.2021.116297_bb0060","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S2213-8587(19)30346-8","article-title":"Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT extension study","volume":"7","author":"McClung","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"7","key":"10.1016\/j.bone.2021.116297_bb0065","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/jbmr.4284","article-title":"Incidence of hip and subtrochanteric\/femoral shaft fractures in postmenopausal women with osteoporosis in the phase 3 long-term odanacatib fracture trial","volume":"36","author":"Papapoulos","year":"2021","journal-title":"J. Bone Miner. Res."},{"issue":"15","key":"10.1016\/j.bone.2021.116297_bb0070","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2021.116297_bb0075","author":"U.S. Food and Drug Administration"},{"issue":"12","key":"10.1016\/j.bone.2021.116297_bb0080","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1002\/jbmr.2565","article-title":"Trends in media reports, Oral bisphosphonate prescriptions, and hip fractures 1996\u20132012: an ecological analysis","volume":"30","author":"Jha","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116297_bb0085","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bone.2016.10.013","article-title":"Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: variation by age, sex, geographic location and ethnicity","volume":"94","author":"van der Velde","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.116297_bb0090","series-title":"The Osteoporosis Treatment Gap, Osteoporosis Treatment","first-page":"97","author":"Curtis","year":"2021"},{"issue":"2","key":"10.1016\/j.bone.2021.116297_bb0095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/BOT.0b013e3181b6499b","article-title":"Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture?","volume":"24","author":"Koh","year":"2010","journal-title":"J. Orthop. Trauma"},{"issue":"12","key":"10.1016\/j.bone.2021.116297_bb0100","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMc0707493","article-title":"Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate","volume":"358","author":"Lenart","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bone.2021.116297_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the american society for bone and mineral research","volume":"29","author":"Shane","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2021.116297_bb0110","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/17453674.2014.885355","article-title":"Atypical fracture of the femur in a patient using denosumab\u2013a case report","volume":"85","author":"Schilcher","year":"2014","journal-title":"Acta Orthop."},{"issue":"5","key":"10.1016\/j.bone.2021.116297_bb0115","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/jbmr.1550","article-title":"Incidence and demography of femur fractures with and without atypical features","volume":"27","author":"Feldstein","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2021.116297_bb0120","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2021.116297_bb0125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13018-015-0332-3","article-title":"Demographic factors in hip fracture incidence and mortality rates in California, 2000\u20132011","volume":"11","author":"Sullivan","year":"2016","journal-title":"J. Orthop. Surg. Res."},{"issue":"4","key":"10.1016\/j.bone.2021.116297_bb0130","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00198-010-1300-8","article-title":"Clinical and demographic factors associated with fractures among older americans","volume":"22","author":"Taylor","year":"2011","journal-title":"Osteoporos. Int."},{"issue":"5","key":"10.1016\/j.bone.2021.116297_bb0135","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11914-019-00525-x","article-title":"The role of lower-limb geometry in the pathophysiology of atypical femoral fracture","volume":"17","author":"Haider","year":"2019","journal-title":"Curr. Osteoporos. Rep."},{"issue":"2","key":"10.1016\/j.bone.2021.116297_bb0140","first-page":"77","article-title":"Distribution of atypical fractures and cortical stress lesions in the femur: implications on pathophysiology","volume":"52","author":"Koh","year":"2011","journal-title":"Singap. Med. J."},{"issue":"4","key":"10.1016\/j.bone.2021.116297_bb0145","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00776-014-0572-9","article-title":"Stress fracture of the bowed femoral shaft is another cause of atypical femoral fracture in elderly japanese: a case series","volume":"19","author":"Oh","year":"2014","journal-title":"J. Orthop. Sci."},{"issue":"1","key":"10.1016\/j.bone.2021.116297_bb0150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/BOT.0b013e31829ff3c9","article-title":"Variation in the femoral bow: a novel high-throughput analysis of 3922 femurs on cross-sectional imaging","volume":"28","author":"Maratt","year":"2014","journal-title":"J. Orthop. Trauma"},{"issue":"11","key":"10.1016\/j.bone.2021.116297_bb0155","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/jbmr.2547","article-title":"Atypical fractures are mainly subtrochanteric in Singapore and diaphyseal in Sweden: a cross-sectional study","volume":"30","author":"Schilcher","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2021.116297_bb0160","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00774-012-0358-0","article-title":"Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series","volume":"30","author":"Sasaki","year":"2012","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2021.116297_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2014.02.006","article-title":"Symptomatic atypical femoral fractures are related to underlying hip geometry","volume":"63","author":"Taormina","year":"2014","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bone.2021.116297_bb0170","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1210\/jc.2012-2972","article-title":"Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial","volume":"98","author":"Brixen","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"24","key":"10.1016\/j.bone.2021.116297_bb0175","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bone.2021.116297_bb0180","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.bone.2021.116297_bb0185","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.bone.2013.02.004","article-title":"Proposed pathogenesis for atypical femoral fractures: lessons from material research","volume":"55","author":"Ettinger","year":"2013","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bone.2021.116297_bb0190","doi-asserted-by":"crossref","first-page":"127","DOI":"10.5371\/hp.2017.29.2.127","article-title":"Lateral femoral bowing and the location of atypical femoral fractures","volume":"29","author":"Yoo","year":"2017","journal-title":"Hip Pelvis"},{"issue":"1","key":"10.1016\/j.bone.2021.116297_bb0195","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3109\/17453674.2015.1004149","article-title":"Risk of atypical femoral fracture during and after bisphosphonate use","volume":"86","author":"Schilcher","year":"2015","journal-title":"Acta Orthop."},{"key":"10.1016\/j.bone.2021.116297_bb0200","series-title":"American Society for Bone and Mineral Research, J Bone Miner Res, Virtual","article-title":"Bisphosphonate use and risk of atypical femoral fractures: a nationwide Danish analysis with blinded radiographic review","author":"Bauer","year":"2020"},{"issue":"2","key":"10.1016\/j.bone.2021.116297_bb0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11914-021-00658-y","article-title":"The genetics of atypical femur fractures-a systematic review","volume":"19","author":"Zhou","year":"2021","journal-title":"Curr. Osteoporos. Rep."},{"issue":"1-2","key":"10.1016\/j.bone.2021.116297_bb0210","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"8","author":"Hernlund","year":"2013","journal-title":"Arch. Osteoporos."},{"issue":"21","key":"10.1016\/j.bone.2021.116297_bb0215","first-page":"2096","article-title":"Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2021.116297_bb0220","author":"N.O.F. American Society for Bone and Mineral Research"},{"key":"10.1016\/j.bone.2021.116297_bb0225","article-title":"Asian ethnicity is associated with atypical femur fractures in an australian population study","volume":"115319","author":"Nguyen","year":"2020","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.bone.2021.116297_bb0230","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00198-019-05002-w","article-title":"Fracture risk following intermission of osteoporosis therapy","volume":"30","author":"Dennison","year":"2019","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2021.116297_bb0235","article-title":"Effect of 6-year treatment of osteoporosis with zoledronic acid 5mg (Aclasta) compared with the 3-yeartreatment, results of extended horizon PFT study","volume":"27","author":"Black","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"7","key":"10.1016\/j.bone.2021.116297_bb0240","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/jbmr.3420","article-title":"Bisphosphonate drug holiday and fracture risk: a population-based cohort study","volume":"33","author":"Adams","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2021.116297_bb0245","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/MLR.0000000000001294","article-title":"Duration of bisphosphonate drug holidays and associated fracture risk","volume":"58","author":"Curtis","year":"2020","journal-title":"Med. Care"},{"issue":"5","key":"10.1016\/j.bone.2021.116297_bb0250","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/jbmr.3654","article-title":"Comparison of BMD changes and bone formation marker levels 3 years after bisphosphonate discontinuation: FLEX and HORIZON-PFT extension I trials","volume":"34","author":"Kim","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"7","key":"10.1016\/j.bone.2021.116297_bb0255","first-page":"1126","article-title":"Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study","volume":"174","author":"Bauer","year":"2014","journal-title":"JAMA"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221004634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221004634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:57:28Z","timestamp":1757613448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328221004634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":51,"alternative-id":["S8756328221004634"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2021.116297","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bisphosphonates and the risk of atypical femur fractures","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2021.116297","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116297"}}